PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Clin Cancer Res. Author manuscript; available in PMC Mar 15, 2013.
Published in final edited form as:
PMCID: PMC3306466
NIHMSID: NIHMS352684
Phospho-specific Flow: Fixating on the target
Mark Levis
Mark Levis, Johns Hopkins University, Oncology, 1650 Orleans Street, CRB 243, Baltimore, MD 21287, United States, 4105023629, 4106147279, (fax)
Mark Levis: levisma/at/jhmi.edu
Summary
Targeted therapies are all the rage in oncology research these days. The problem remains as to how to confirm that the target is actually being hit in vivo. This report describes the application of phospho-specific flow cytometry to establish in vivo target inhibition in real-time.
In this issue of Clinical Cancer Research, Perl et al detail the successful use of phospho-specific flow cytometry to assess real-time mTOR inhibition by sirolimus in a clinical trial of acute myeloid leukemia (AML) patients (1). The technique they describe has the potential to be an effective method of determining target inhibition for any number of agents used to inhibit kinase pathways in clinical cancer trials.
At the center of this report is a clinical trial in which patients with relapsed, refractory, or otherwise high risk AML were treated with a combination of chemotherapy and a targeted agent, sirolimus. Like so many such endeavors in oncology, the trial was based on a significant body of pre-clinical data. The mammalian target of rapamycin (mTOR) is postulated to play a critical role in chemotherapy resistance. Previous work from this group indicated that the combination of mTOR inhibitors with chemotherapy results in synergistic cytotoxicity in AML cells in vitro (2). The design of the trial, therefore, is relatively simple: Administer intensive chemotherapy after loading the patient with sirolimus (rapamycin). Importantly, however, the central hypothesis being tested in this trial is not that sirolimus will be of benefit, but rather that inhibition of mTOR will be of benefit. A plasma drug level of sirolimus (or any other targeted agent) is easy enough to measure, but how do the investigators know that mTOR is actually being inhibited in the malignant cells of the patient receiving the therapy?
Ever since the advent of modern targeted therapies, the need to determine the efficacy of target inhibition in vivo has been apparent. The concept is easy in principle, but daunting from a technical standpoint. The direct biochemical measurement of the targeted protein or cellular function within the malignant cells from the patient undergoing the treatment could be put forth as a gold standard, but that standard is rarely, if ever, achieved, particularly in trials of solid tumors. This has necessitated the use of surrogate tissue such as skin biopsies for EGFR inhibitors (3). Researchers conducting trials in leukemia patients often have an advantage in this regard, because the targeted tissue can be sampled with the relatively minimal invasiveness of a blood draw. Inhibition of BCR-ABL in chronic myelogenous leukemia (CML) patients by imatinib, for example, was tracked with de-phosphorylation of Crk-L (4). CML, however, is somewhat unique in that there is typically a large tumor burden available for sampling. Other leukemias are less accommodating- AML can present with a relatively low blast count in the peripheral blood. To make matters more difficult, when a targeted therapy is combined with chemotherapy, the blasts are cleared from the blood quickly, and yet maintaining target inhibition in the marrow blasts (the real target) is paramount. In such cases, a surrogate measurement such as the plasma inhibitory activity (PIA) assay may be employed (5). This approach also has its drawbacks, in that the target inhibition is being measured in a surrogate tumor cell type, rather than the actual malignant cells being treated in the patient.
In what may represent an important new advance in translational oncology, Perl and colleagues have devised a means of tracking target inhibition in just a few thousand cells isolated in real time from patients on a clinical trial (1). Patients with relapsed or otherwise high risk AML were loaded with sirolimus, then treated with a conventional salvage chemotherapy regimen (mitoxantrone, etoposide, and cytarabine, “MEC”) while still receiving sirolimus. Whole blood samples were collected at baseline, Day 4, and Day 7 of treatment. Within 1 hour of collection, a small volume of formaldehyde was added to the blood in order to fix the cells (Figure 1). In formaldehyde fixation, proteins are cross-linked, typically at lysine residues (6). In this case, that means the signaling effects of sirolimus are essentially “frozen” in time immediately after collection. The red blood cells can be removed from the sample by lysis, and then the fixed white blood cells can be analyzed immediately or stored frozen. Flow cytometric analysis of these white blood cells using conventional cell surface markers such as CD45 and CD33 allow easy identification of blasts. The tricky part of this assay is to analyze the intracellular signaling proteins within the gated blasts. Sirolimus inhibits the mTORC1 subunit of mTOR, leading to loss of phosphorylation of the ribosomal protein S6 kinase (7). Therefore, this assay is predicated on the ability to accurately measure the level of S6 phosphorylation in these fixed cells. Permeabilizing the fixed cells with methanol allows access of an anti-phospho-S6 antibody to the interior of the cell. Direct target inhibition within the blasts can thus be quantified in reproducible fashion.
Figure 1
Figure 1
Analyzing patient samples with phospho-specific flow
The advantages of this technique are immediately obvious. This is real-time measurement of target inhibition within the patient’s actual cancer cells. Only a small number of malignant cells are needed, so patients with low blast counts can be included in these studies. The reagents used are common, and flow cytometry is used by any center conducting clinical trials. Moreover, the samples can be collected, fixed, and then shipped to a central laboratory for the phospho-flow, so multi-center trials can easily accommodate this approach for their correlative studies.
This innovative study actually represents a step in a logical progression that began with the development of phospho-specific flow (89), which has thus far been limited to examining fluctuations in a select group of phospho-proteins (10). However, multi-parameter flow cytometry as practiced now remains constrained by the number of wavelength available on the machine. The group that spearheaded the development of phospho-specific flow cytometry is now exploring a much more powerful approach to analyzing signaling changes in single cells-Mass Cytometry (11). In this exciting new technique (which seems destined to be applied to a clinical trial setting soon), antibodies to a wide array of signaling proteins are labeled with stable isotopes, each one representing a unique signature detectable by mass spectrometry analysis. The only limiting issue remains the specificity and avidity of the antibodies.
There are, of course, drawbacks. The approach as it stands now is probably only applicable to the various types of leukemia. Cross-linking of proteins by formaldehyde may actually obscure or alter the ability of an antibody to bind to an epitope, potentially introducing a significant artifact into this system. The antibody to the phosphorylated epitope may lack sensitivity, or worse, specificity, rendering the results useless. Certainly, anyone planning to apply this approach to clinical correlative studies will first need to carefully validate it for the target in question before sample accrual begins.
Nonetheless, these are encouraging results. Phospho-flow analysis of intracellular signaling has been under development for several years now (12) but the work by Perl et al represents one of the first successful applications of the technique to a translational oncology clinical trial. It seems likely that others will soon follow.
1. Perl AE, Kasner MT, Shank D, Luger SM, Carroll M. Single-cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts During a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemotherapy. Clin Cancer Res. 2012:18. [PMC free article] [PubMed]
2. Xu Q, Thompson JE, Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood. 2005;106:4261–8. [PubMed]
3. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 2002;20:4292–302. [PubMed]
4. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–7. [PubMed]
5. Levis M, Brown P, Smith BD, Stine A, Pham R, Stone R, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006;108:3477–83. [PubMed]
6. Nadeau OW, Carlson GM. Protein Interactions Captured by Chemical Cross-linking: One-Step Cross-linking with Formaldehyde. CSH Protoc. 2007;2007:pdb prot4634. [PubMed]
7. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12:21–35. [PMC free article] [PubMed]
8. Perez OD, Nolan GP. Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry. Nat Biotechnol. 2002;20:155–62. [PubMed]
9. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, Gjertsen BT, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell. 2004;118:217–28. [PubMed]
10. Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell. 2008;14:335–43. [PMC free article] [PubMed]
11. Bendall SC, Simonds EF, Qiu P, Amir el AD, Krutzik PO, Finck R, et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science. 2011;332:687–96. [PMC free article] [PubMed]
12. Suni MA, Maino VC. Flow cytometric analysis of cell signaling proteins. Methods Mol Biol. 2011;717:155–69. [PubMed]